Rain Oncology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Rain Oncology şirketinin toplam hissedar öz sermayesi $67.5M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $82.1M ve $14.5M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$77.34m
Eşitlik	US$67.52m
Toplam yükümlülükler	US$14.54m
Toplam varlıklar	US$82.06m

Son finansal sağlık güncellemeleri

Is Rain Oncology (NASDAQ:RAIN) In A Good Position To Invest In Growth?

Feb 23

We Think Rain Therapeutics (NASDAQ:RAIN) Needs To Drive Business Growth Carefully

Nov 08

Here's Why We're Watching Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Situation

Aug 03

We're Not Very Worried About Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Rate

Apr 17

Recent updates

Is Rain Oncology (NASDAQ:RAIN) In A Good Position To Invest In Growth?

Feb 23

We Think Rain Therapeutics (NASDAQ:RAIN) Needs To Drive Business Growth Carefully

Nov 08

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: RAIN 'nin kısa vadeli varlıkları ( $80.8M ) kısa vadeli yükümlülüklerini ( $14.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: RAIN şirketinin kısa vadeli varlıkları ( $80.8M ) uzun vadeli yükümlülüklerini ( $64.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: RAIN borçsuzdur.

Borcun Azaltılması: RAIN un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: RAIN şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: RAIN serbest nakit akışı her yıl % 42.8 1.1 yıl yetecek nakit akışına sahip olacaktır.

Rain Oncology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Rain Oncology Files Form 15

Rain Oncology to Delist from Nasdaq

Is Rain Oncology (NASDAQ:RAIN) In A Good Position To Invest In Growth?

We Think Rain Therapeutics (NASDAQ:RAIN) Needs To Drive Business Growth Carefully

Here's Why We're Watching Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Situation

We're Not Very Worried About Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Rate

Recent updates

Rain Oncology Files Form 15

Rain Oncology to Delist from Nasdaq

Pathos AI, Inc. entered into a definitive merger agreement to acquire Rain Oncology Inc. (NasdaqGS:RAIN) for $42.2 million.

Pathos AI, Inc. entered into a definitive merger agreement to acquire Rain Oncology Inc. (NasdaqGS:RAIN) for $42.2 million.

New minor risk - Shareholder dilution

Price target decreased by 69% to US$1.44

Price target decreased by 30% to US$4.65

Rain Oncology Inc., Proterra Inc., Bioxcel Therapeutics, Inc Announces Class Action Update

Rain Oncology Inc. to Report Q2, 2023 Results on Aug 10, 2023

Levi & Korsinsky, LLP Files a Complaint to Recover Losses Suffered by Purchasers of Rain Oncology Inc. Securities

Price target decreased by 59% to US$7.46

Rain Oncology Inc. Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for Treatment of Dedifferentiated Liposarcoma

Price target increased by 7.4% to US$19.44

Is Rain Oncology (NASDAQ:RAIN) In A Good Position To Invest In Growth?

Rain Oncology Inc. Announces Phase 1 Clinical Data of Milademetan Publishes in Journal of Clinical Oncology

Senior VP & Head of Research notifies of intention to sell stock

lead Independent Director recently bought US$988k worth of stock

We Think Rain Therapeutics (NASDAQ:RAIN) Needs To Drive Business Growth Carefully

Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for Mdm2-Amplified Advanced Solid Tumors

Rain Therapeutics Inc. to Report Q3, 2022 Results on Nov 10, 2022

Price target decreased to US$18.00

Rain Therapeutics Inc. Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma

Rain Therapeutics GAAP EPS of -$0.66 in-line

Here's Why We're Watching Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Situation

Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russell 2500 Value Index

Co-Founder recently bought US$57k worth of stock

Price target decreased to US$16.17

Price target decreased to US$18.00

Rain Therapeutics Inc., Annual General Meeting, Jun 01, 2022

We're Not Very Worried About Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Rate

Co-Founder notifies of intention to sell stock

Rain Therapeutics Inc. Announces the Appointments of Several Industry Veterans to the Leadership Team

We Think Rain Therapeutics (NASDAQ:RAIN) Can Afford To Drive Business Growth

Independent Director recently bought US$54k worth of stock

We're Hopeful That Rain Therapeutics (NASDAQ:RAIN) Will Use Its Cash Wisely

Rain Therapeutics Inc. Presents Non-Clinical Data on Milademetan (RAIN-32) in Malignant Pleural Mesothelioma at the IASLC 2021 World Conference on Lung Cancer

Independent Director recently bought US$2.1m worth of stock

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin